

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement*



**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**  
**(深圳市海普瑞藥業集團股份有限公司)**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 9989)**

**NOTICE OF THE 2022 ANNUAL GENERAL MEETING**

**NOTICE IS HEREBY GIVEN** that the 2022 annual general meeting (the “**AGM**”) of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) will be held at 2:30 p.m. on Monday, May 22, 2023 at Ballroom, 2/F, L’Hermitage Hotel, 3031 Nanhai Boulevard, Nanshan District, Shenzhen, the PRC for the purpose of considering, and if thought fit, passing the following resolutions. Unless otherwise indicated, capitalized terms used herein shall have the same meanings as defined in the circular of the Company dated April 20, 2023.

**ORDINARY RESOLUTIONS**

To consider and pass the following ordinary resolutions by way of non-cumulative voting:

1. The resolution regarding the 2022 Work Report of the Board of Directors of the Company;
2. The resolution regarding the 2022 Work Report of the Supervisory Committee;
3. The resolution regarding the 2022 Annual Report and its Summary, H Share Results Announcement, H Shares 2022 Annual Report, 2022 Corporate Governance Report and 2022 Environmental, Social and Governance Report of the Company;
4. The resolution regarding the 2022 Final Financial Report of the Company;
5. The resolution regarding the 2022 Profit Distribution Proposal of the Company;

## **SPECIAL RESOLUTIONS**

To consider and pass the following special resolutions by way of non-cumulative voting:

6. The resolution regarding the purchase of wealth management products and cash flow management using internal funds;
7. The resolution regarding the application for credit line and providing guarantee to certain banks for 2023 of the Company;

## **ORDINARY RESOLUTION**

To consider and pass the following ordinary resolution by way of non-cumulative voting:

8. The resolution regarding the re-appointment of auditors of the Company;

## **SPECIAL RESOLUTION**

To consider and pass the following special resolution by way of non-cumulative voting:

9. The resolution regarding the amendments to the Articles of Association;

## **ORDINARY RESOLUTIONS**

To consider and pass the following ordinary resolution by way of non-cumulative voting:

10. The resolution regarding the remuneration of the independent Directors of the sixth session of the Board;

To consider and pass the following ordinary resolution by way of cumulative voting:

11. The resolution regarding the election of non-independent Directors of the sixth session of the Board:
  - 11.01 The resolution regarding the re-election of Mr. Li Li as a non-independent Director of the Company;
  - 11.02 The resolution regarding the re-election of Ms. Li Tan as a non-independent Director of the Company;
  - 11.03 The resolution regarding the re-election of Mr. Shan Yu as a non-independent Director of the Company; and
  - 11.04 The resolution regarding the appointment of Mr. Zhang Ping as a non-independent Director of the Company.

12. The resolution regarding the election of independent non-executive Directors of the sixth session of the Board:
- 12.01 The resolution regarding the re-election of Dr. Lu Chuan as an independent non-executive Director of the Company;
  - 12.02 The resolution regarding the appointment of Mr. Huang Peng as an independent non-executive Director of the Company; and
  - 12.03 The resolution regarding the appointment of Mr. Yi Ming as an independent non-executive Director of the Company.
13. The resolution regarding the re-election of non-employee Supervisors of the sixth session of the Supervisory Committee:
- 13.01 The resolution regarding the re-election of Mr. Zheng Zehui as a non-employee Supervisor of the Company; and
  - 13.02 The resolution regarding the appointment of Ms. Tang Haijun as a non-employee Supervisor of the Company.

By order of the Board  
**Shenzhen Hepalink Pharmaceutical Group**  
**Co., Ltd.**  
**Li Li**  
*Chairman*

Shenzhen, PRC  
April 20, 2023

*Notes:*

1. The register of members of the Company's H shares will be closed from May 17, 2023 to May 22, 2023 (both days inclusive), during which period no transfer of H shares will be effected. In order for H share shareholders to be qualified to attend and vote at the AGM, all transfer documents accompanied by the relevant share certificates must be lodged with the H Shares registrar of the Company, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, no later than 4:30 p.m. on May 16, 2023 for registration.

The H share shareholders whose names appear on the register of members of the Company's H shares on May 22, 2023 are entitled to attend and vote at the AGM.

2. H share shareholders who are entitled to attend and vote at the AGM may appoint one or more proxies to attend and vote on their behalves. A proxy need not be a shareholder.
3. The instrument appointing a proxy must be in writing under the hand of a shareholder or his attorney duly authorised in writing. If the shareholder is a legal person, that instrument must be executed either under its seal or under the hand of its director or other attorney duly authorised to sign the same on its behalf.
4. In order to be valid, the proxy form must be deposited, for H share shareholders, to the H Shares registrar of the Company, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not less than 24 hours before the time for holding the AGM. If the proxy form is signed by a person under a power of attorney or other authority, a notarized copy of that power of attorney or other authority shall be deposited at the same time as mentioned in the proxy form. Completion and return of the proxy form will not preclude the shareholders from attending and voting in person at the AGM or any adjourned meetings should they so wish.
5. Shareholders shall produce their identification documents and supporting documents in respect of the shares of the Company held when attending the AGM. If corporate shareholders appoint authorised representative to attend the AGM, the authorised representative shall produce his/her identification documents and a notarized copy of the relevant authorisation instrument signed by the board of directors or other authorised parties of the corporate shareholders or other notarized documents allowed by the Company. Proxies shall produce their identification documents and the proxy form signed by the shareholders or their attorney when attending the AGM.
6. The AGM is expected to take for less than half a day. Shareholders attending the AGM shall be responsible for their own travel and accommodation expenses.
7. All voting at the AGM will be conducted by poll.

8. Regarding ordinary resolutions number 11 to 13, a cumulative voting system will be adopted. “Cumulative voting system” refers to a system of voting for election of Directors or Supervisors at general meetings under which each Share shall be entitled to the number of votes equivalent to the number of the Directors or Supervisor(s) to be elected at the Shareholders’ general meeting. Shareholders may consolidate their votes for one or more Director(s) or Supervisor(s). The principles below shall be followed for voting under the cumulative voting system:
- (i) the number of candidates for the roles of Directors or Supervisor(s) may be greater than that of the Directors or Supervisor(s) to be elected at the Shareholders’ general meeting, but the number of candidates to be voted by each Shareholder shall not exceed the number of Directors or Supervisor(s) to be elected at the Shareholders’ general meeting, and the total number of votes allocated to the Shareholders shall not exceed the number of votes held by them; otherwise, the votes shall be invalid;
  - (ii) voting for the non-independent Directors and independent non-executive Directors shall be carried out separately. For the election of independent non-executive Directors, the number of votes each Shareholder is entitled to shall be equal to the number of Shares held by the Shareholder multiplied by the number of independent non-executive Directors to be elected, and such votes must be cast only for the candidates for the role of the Company’s independent non-executive Directors; for the election of non-independent Directors, the number of votes each Shareholder is entitled to shall be equal to the number of Shares held by the Shareholder multiplied by the number of non-independent Directors to be elected, and such votes must be cast only for the candidates for the role of the Company’s non-independent directors; and
  - (iii) the candidates to be finally elected as Directors or Supervisors shall be determined according to the numbers of votes they have received, but the minimum number of votes each candidate elected has received must exceed half of the total number of Shares held by Shareholders (including proxies thereof) attending the AGM. If the number of Directors or Supervisors elected falls short of the number of Directors or Supervisors to be elected at the AGM, a new round of voting shall be carried out for the candidates for the roles of Directors or Supervisors not having received the required number of votes to fill the shortage. If the shortage is still not filled, a by-election shall be conducted at the next Shareholders’ general meeting of the Company. If two or more candidates for the roles of Directors or Supervisors have the same number of votes, but not all of them can be elected according to the election quota, a separate round of voting shall be conducted for such candidates with the same number of votes.
9. References to times and dates of this notice are to Hong Kong times and dates.

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan and Mr. Shan Yu; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.*